- Lilly's Trulicity OK'd; can it top GLP-1 market?
- How AstraZeneca's revivified pipeline could boost Pfizer
- Phase III diabetes data give Intarcia (and doctors, patients) options
- More joy for Lilly as dulaglutide gets EU go-ahead
- INTERVIEW: Novo CEO downplays Afrezza, pins hopes on oral pipeline
- INTERVIEW: Clinuvel's Philippe Wolgen on Scenesse and the patient factor
JOB OF THE WEEK Promote your job vacancy